EpiCept's request for continued listing on the Nasdaq Stock Market granted by Nasdaq Hearings Panel

NewsGuard 100/100 Score

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that a Nasdaq Hearings Panel has granted the Company’s request for continued listing on The Nasdaq Stock Market. The Company’s continued listing is subject to the Company’s satisfaction of the condition that on or before February 1, 2010, the Company evidence a closing bid price of at least $1.00 per share for a minimum of ten prior consecutive trading days (or, under certain circumstances, such longer period as the Panel may determine).

As previously announced, on August 3, 2009, EpiCept received notice from Nasdaq that it had not regained compliance with the minimum bid price requirement and that the Company’s securities were subject to delisting unless it requested a hearing before a Nasdaq Hearings Panel. The Company requested a hearing and appeared before the Panel on September 23, 2009. On November 2, 2009, the Panel rendered its determination to continue the Company’s listing.

The Company expects to timely comply with the terms of the Panel’s decision; however, there can be no assurance that the Company will be able to do so.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Association of volatile aromatic compounds in blood with hearing impairment